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ABSTRACT  97 
Purpose: Acrylamide was classified as ‘probably carcinogenic’ to humans in 1994 by the International 98 
Agency for Research on Cancer. In 2002, public health concern increased when acrylamide was 99 
identified in starchy, plant-based foods, processed at high temperatures. The purpose of this study was 100 
to identify which food groups and lifestyle variables were determinants of hemoglobin adduct 101 
concentrations of acrylamide (HbAA) and glycidamide (HbGA) in 801 non-smoking postmenopausal 102 
women from 8 countries in the European Prospective Investigation into Cancer and Nutrition (EPIC) 103 
cohort.  104 
Methods: Biomarkers of internal exposure were measured in red blood cells (collected at baseline) by 105 
HPLC/MS/MS (high-performance liquid chromatography/tandem mass spectrometry). In this cross-106 
sectional analysis four dependent variables were evaluated: HbAA, HbGA, sum of total adducts 107 
(HbAA+HbGA), and their ratio (HbGA/HbAA). Simple and multiple regression analyses were used to 108 
identify determinants of the four outcome variables. All dependent variables (except HbGA/HbAA), 109 
and all independent variables were log-transformed (log2) to improve normality. Median (25th-110 
75thpercentile) HbAA and HbGA adducts levels were 41.3 (32.8-53.1) pmol/g Hb and 34.2 (25.4-46.9) 111 
pmol/g Hb, respectively.  112 
Results: The main food group determinants of HbAA, HbGA, HbAA+HbGA were biscuits, crackers, 113 
and dry cakes. Alcohol intake and body mass index were identified as the principal determinants of 114 
HbGA/HbAA. The total percent variation in HbAA, HbGA, HbAA+HbGA, and HbGA/HbAA 115 
explained in this study was 30%, 26%, 29%, and 13%, respectively.  116 
Conclusions: Dietary and lifestyle factors explain a moderate proportion of acrylamide adduct 117 
variation in non-smoking postmenopausal women from the EPIC cohort. 118 
Key words (4 to 6): acrylamide; glycidamide; hemoglobin adducts; biomarkers; diet; nutrition.  119 
  120 
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INTRODUCTION  121 
Acrylamide was identified in food in 2002, and is mainly formed through the Maillard reaction 122 
whereby a carbonyl compound (a reducing sugar, such as glucose or fructose) reacts with the amino 123 
group of asparagine processed at high temperatures (>120 ºC; i.e. frying, baking, or roasting) [1, 2]. 124 
Nevertheless, acrylamide has also been found in foods cooked at temperatures lower than 100ºC (e.g. 125 
prune juice) [3]. Thus, levels of acrylamide in foods depend on factors such as temperature and length 126 
of cooking time, water content, and the amount of both reducing sugars and asparagine levels present 127 
in foods [4]. Freisling et al. assessed the principal food group determinants of acrylamide intake based 128 
on a 24-h dietary recall (24hDR) in 13,486 men and 23,508 women from the European Prospective 129 
Investigation into Cancer and Nutrition (EPIC) cohort, and identified bread, crisp bread, rusks, coffee, 130 
and potatoes [5].  131 
Once acrylamide is consumed, it is absorbed in the gastrointestinal tract and, via the circulation, is 132 
distributed to peripheral tissues [6, 7]. In the body, acrylamide is metabolized to glycidamide mainly 133 
by the cyp2e1 enzyme complex, and is conjugated with reduced glutathione for elimination. 134 
Acrylamide is neurotoxic in animals and in humans, but only glycidamide is considered to have 135 
mutagenic and genotoxic properties [1, 8]. As a consequence of animal and in vitro studies, the 136 
International Agency for Research on Cancer (IARC) classified acrylamide as ‘probably carcinogenic’ 137 
to humans [9].  138 
Acrylamide and glycidamide can bind to N-terminal valine of hemoglobin (Hb) in red blood cells, and 139 
form adducts, both of which are considered valid biomarkers that reflect human internal exposure 140 
within the last 120 days (the average lifespan of erythrocytes) [1, 10]. Tobacco smoking is an 141 
important source of acrylamide exposure, and smokers have been observed to have mean Hb adducts 142 
levels three to four times higher than non-smokers [11–13]. 143 
Two previous EPIC studies evaluated biomarkers of acrylamide measured as acrylamide and 144 
glycidamide Hb-adducts (HbAA and HbGA, respectively). The first study, published by Vesper et al., 145 
aimed to determine acrylamide exposure variability (both at the individual- and group/country-level) 146 
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in 240 men and 270 women, and at the same time, determine which non-dietary factors could play a 147 
role in this variability [14]. The second study, published by Ferrari et al., was conducted with the 148 
intention to compare HbAA and HbGA levels with total estimated dietary acrylamide intakes assessed 149 
using dietary questionnaires (DQs), and a 24hDR in 240 men and 270 women to estimate the validity 150 
of the EPIC dietary acrylamide assessment [15]. The main objective of the present study, which 151 
differed from the two former EPIC studies, was to identify which food groups and lifestyle factors 152 
(assessed through country-specific DQs and lifestyle questionnaires) were determinants of HbAA and 153 
HbGA concentrations in a subgroup of non-smoking postmenopausal women from the EPIC cohort. 154 
The relation between intakes of several food items using DQs, and HbAA and HbGA adducts levels 155 
has been previously evaluated in three different studies [16–18]. 156 
MATERIALS AND METHODS 157 
Study population and data collection 158 
The EPIC study comprises 23 research centers in 10 European countries, and was designed to evaluate 159 
the relation between nutrition and lifestyle factors and the incidence of cancer and other chronic 160 
diseases. The present study includes 8 of the 10 participating EPIC countries: France, Germany, Spain, 161 
the United Kingdom (UK), Greece, Italy, The Netherlands, and Sweden (Umeå). Norway and 162 
Denmark did not participate in this analysis (EPIC-Denmark published their results separately as the 163 
Diet, Cancer, and Health cohort) [17]. 164 
The methodology of the EPIC study has been previously described [19]; all local ethics committees, 165 
and/or the IARC ethical review boards approved the study. Briefly, recruitment started between 1992-166 
1998, and all EPIC participants provided information on habitual diet through country-specific 167 
validated DQs, referring to the year before recruitment. Information on tobacco smoking, physical 168 
activity, and education were assessed using country-specific questionnaires. Anthropometric measures 169 
(height, weight, and waist or hip circumference) were obtained at baseline by trained personnel; 170 
however, participants from France and Oxford (UK) cohorts self-reported their height and weight. 171 
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Umeå (Sweden), did not collect information on waist or hip circumference, and only 29% participants 172 
from France had information on these anthropometric measures.  173 
Blood samples (serum, plasma, white blood cells, and erythrocytes) were collected at recruitment for 174 
385,747 of the over 500,000 EPIC participants, and were stored in liquid nitrogen (-196ºC) at the 175 
central biological bank located at IARC; blood samples from Umeå were kept in freezers (-80ºC) at 176 
local repositories [19]. The present study population comprises control women from two published 177 
nested case-control studies of acrylamide hemoglobin adducts levels and ovarian and endometrial 178 
cancers risk in EPIC [20, 21]. The selection of cases and controls for these two nested-case control 179 
studies followed the protocol that has been previously described by Cust et al. and Peeters et al. [22, 180 
23]. Briefly, two controls (free of cancer, with the exception of non-melanoma skin cancer) were 181 
randomly selected using an incidence density sampling protocol, for each case subject (ovarian or 182 
endometrial cancer case) at the time of diagnosis.  Matching criteria for both cases and controls 183 
included study center, menopausal status (premenopausal, postmenopausal, ‘undefined’), age at 184 
recruitment, (±6 months), time of day of blood draw (±1 hour), fasting status (<3, 3-6, >6 hours). For 185 
the present study, only women who were postmenopausal at blood draw, and non-smokers at 186 
recruitment were selected, since it has been postulated that acrylamide may disrupt hormonal balance, 187 
and it is known that smoking contributes to Hb-adducts levels. Postmenopausal status refers to women 188 
who reported having had the last menstrual period more than 1 year before recruitment, or when they 189 
were more than 55 years old [23]. The category of non-smoking women includes those women who 190 
reported being never smokers or having quit smoking 5 or more years before recruitment. 191 
Thus, a total of 802 non-smoking postmenopausal control women (416 and 386 controls from the 192 
ovarian and the endometrial nested case-control studies, respectively) were available for the present 193 
study. One participant was excluded from analyses because she did not have information on HbGA 194 
adduct level, leaving a total of 801 observations  195 
Assessment of dietary acrylamide intake 196 
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The methodology followed to create the EPIC acrylamide database has been previously described [15, 197 
24]. In brief, the EPIC acrylamide database was assembled using information on average acrylamide 198 
levels in foods from an EU monitoring database (maintained by the European Community Institute for 199 
Reference Materials and Measurements; IRMM), and the frequency of consumption of these foods 200 
using country-specific DQs and the EPIC-Soft food classification. 201 
Measurement of acrylamide and glycidamide hemoglobin adducts  202 
The methodology to measure HbAA and HbGA in EPIC has been previously described [14, 15]. 203 
Briefly, 300 μL of hemolysed erythrocytes were used to measure HbAA and HbGA, and were 204 
analyzed by HPLC/tandem mass spectrometry (HPLC/MS/MS) as has been published elsewhere [12, 205 
25]. All blood samples were measured and analyzed in a randomized and blinded manner. Two 206 
independent adduct measures per sample were performed. Hemoglobin adduct concentrations were 207 
reported as the average of these two measurements relative to the amount of hemoglobin. The 208 
detection limits for this method were 3 and 4 pmol/g Hb for HbAA and HbGA, respectively. 209 
Additionally, 42 (5%) blood samples from the same participants were sent in duplicate to evaluate the 210 
reproducibility of the hemoglobin adducts measurements. 211 
Statistical methods 212 
All continuous variables included in the analysis were assessed for normality using the Kolmogorov-213 
Smirnov test, and were log-transformed (log2) in order to reduce skewness. To account for zeroes in 214 
dietary and lifestyle variables, a log2(x + 0.1) transformation was applied. Regarding adduct values, 215 
four outcomes were evaluated: log-transformed HbAA adducts (log2HbAA), log2HbGA, sum of total 216 
adducts [log2(HbAA + HbGA)], and HbGA/HbAA ratio. Simple and multiple linear regression 217 
analyses were used to assess the associations between each of the four outcome variables and food 218 
consumption and lifestyle data. 219 
The following dietary variables and food groups were evaluated to build the HbAA, HbGA, and 220 
HbAA+HbGA final models: total energy, total carbohydrates, total fat, total fiber, total proteins, 221 
starch, potatoes, ‘vegetables’, ‘fruits, nuts and seeds’, ‘cereal and cereal products’, ‘meat and meat 222 
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products’[26], ‘cakes and biscuits’, ‘flour, flakes, starches, and semolina’, ‘pasta, rice, and other 223 
grains’, ‘bread, crisp bread, and rusks’, ‘breakfast cereals’, ‘salty biscuits, aperitif biscuits, and 224 
crackers’, ‘dry cakes and biscuits’, ‘bread’, ‘pastries’, ‘olives’, ‘deep frying fats’, ‘chocolate, candy, 225 
paste, confetti’, ‘snacks’, ‘bread, and pizza dough’, ‘olive oil’, ‘coffee’, ‘decaffeinated coffee’, and 226 
‘tea’. Then, a correlation matrix was performed to identify interdependency between dietary variables. 227 
Variables that were not correlated (r <0.6), that were matching factors for both nested case-control 228 
studies (country was used instead of center due to the number of observations), and ‘type of control’ 229 
(endometrial, ovarian control) were selected for building the final models. Lifestyle variables such as 230 
alcohol intake (g/day) and body mass index (kg/m2; BMI) were also investigated as they may affect 231 
the activity of Cyp2e1 [5, 27]. 232 
Stepwise selection was used to build models for HbAA, HbGA, and HbAA+HbGA adduct outcome 233 
variables. Matching factor and ‘type of control’ variables were forced to be included in the stepwise 234 
selection, and covariates were included in the model if they met the 0.10 significance level. Stepwise 235 
selection was also performed with all food items energy-adjusted using the residual method [28], but 236 
according to the Akaike Information Criterion (AIC) [29], these models were not optimal compared to 237 
those without energy-adjusted food items. 238 
Lifestyle variables such as physical activity using the Cambridge index [30], education level (none, 239 
primary, technical/professional, secondary, and higher education), history of diabetes (yes, no, 240 
unknown), ever use of oral contraceptives (OCs), and ever use of hormone replacement therapy (HRT) 241 
were also evaluated; however, were not included in HbAA, HbGA, and HbAA+HbGA final models 242 
because they did not have an effect on β-estimates.  243 
The HbGA/HbAA ratio model only included lifestyle variables described above (BMI, physical 244 
activity, education level, history of diabetes, OCs use, HRT use, and alcohol intake), since the ratio of 245 
HbGA/HbAA may reflect the metabolism of acrylamide to glycidamide.  246 
Intraclass correlation coefficients (ICC) were estimated to evaluate the reproducibility of acrylamide 247 
measurements using 42 duplicate blood samples from the same participants [31]. Analyses stratified 248 
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by alcohol intake (never drinkers, drinkers), by BMI (<25, 25-30, ≥30 kg/m2), and by European region 249 
(Northern countries: the UK, The Netherlands, Germany, Sweden; Southern countries: France, Italy, 250 
Spain, Greece) were also performed. A Wilcoxon signed-rank test was used to assess differences in 251 
Hb-adducts levels by alcohol intake, BMI, and second-hand smoke exposure (SHS). Variables for 252 
SHS were not evaluated in final models due to the large number of missing values (>50%). R square 253 
(R2) values were used to describe the percent variation in Hb-adduct levels explained by the 254 
independent variables. Partial R2 values for each of the selected variables in the models were estimated 255 
using Type II sums of squares. Pearson’s correlation coefficients for continuous variables were also 256 
estimated. To test whether the slope of a regression line differed significantly from zero, Student’s t 257 
statistics and the corresponding P-values were used. All statistical tests were evaluated at α-level 0.05.  258 
All analyses were performed using SAS v. 9.1 (Cary, North Carolina, USA). Graphics were created 259 
using R v. 3.1.  260 
RESULTS 261 
Correlation Matrix 262 
Total carbohydrates was correlated with total fiber, total proteins, starch, and ‘cereal and cereal 263 
products’. Total fat was correlated with total proteins. Starch was correlated with ‘cereal and cereal 264 
products’. Thus, total carbohydrates, total fat, and starch were excluded from the analyses because 265 
these were larger groups of foods.  266 
Dietary acrylamide intake and baseline characteristics 267 
The median (25th-75th percentile) acrylamide intake at baseline based on DQ information was 20.3 268 
(13.5-29.9) μg/day. The median (25th-75th percentile) estimated dietary acrylamide in relation to body 269 
weight was 0.3 (0.2-0.5) μg/kg-body weight/day. The highest median intakes were found in the UK, 270 
the Netherlands, and Germany, whereas Italy had the lowest median intake (Table1).  271 
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The median (25th-75th percentile) age in the present subcohort of women was 59 (54-63) years. Means 272 
and standard deviations, as well as medians and 25th-75th percentiles are presented for all dietary and 273 
lifestyle variables that were used in all analyses (Supplemental Table1). 274 
Hemoglobin adducts of acrylamide and glycidamide 275 
The ICC for the present study based on 42 duplicates was 0.96 for HbAA and 0.95 for HbGA.  276 
The median (25th-75th percentile) HbAA and HbGA adducts level were 41.3 (32.8-53.1) and 34.2 277 
(25.4-46.9) pmol/g of Hb, respectively (Table1). The highest median HbAA adduct level was 278 
observed in the UK, The Netherlands, and Spain, while Greece had the lowest HbAA levels, followed 279 
by Italy. Regarding HbGA adduct levels, the highest medians were found in the UK, Spain, and The 280 
Netherlands, and the lowest median was also found in Greece and Italy (Table1). The geometric 281 
means for HbAA and HbGA adducts in the total dataset were 5.3 and 5.1 pmol/g Hb respectively (data 282 
not shown). Values for HbAA+HbGA, and HbGA/HbAA by EPIC country are also presented in Table 283 
1.  284 
Regarding differences in Hb-adducts levels by alcohol intake and by BMI, only the ratio 285 
HbGA/HbAA differed (never vs ever drinkers, P-value <0.0001; <25, 25 to <30, ≥30 kg/m2, P-value 286 
<0.0001) (Figure 1, and Figure 2 respectively). No statistically significant differences in Hb-adduct 287 
levels were observed between women who reported being exposed to SHS (n=95) and who were not 288 
exposed (n=149) (data not shown).  289 
Simple linear regression analyses 290 
The crude Pearson’s correlation coefficient between log2-acrylamide intake and log2HbAA was 0.36, 291 
between log2-acrylamide intake and log2HbGA was 0.35, between log2-acrylamide intake and 292 
log2(HbAA+HbGA) was 0.37, and between log2HbAA and log2HbGA was 0.86 (all P-values 293 
<0.0001). Log2HbAA was inversely associated with BMI (P-value <0.0001) and positively associated 294 
with alcohol intake (P-value= 0.04). A statistically significant inverse association was found between 295 
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HbGA/HbAA ratio and alcohol intake (P-value <0.0001), whereas a positive association was observed 296 
between HbGA/HbAA ratio and BMI (P-value <0.0001) (Table 2).  297 
Multiple linear regression analyses 298 
Four multivariable linear regression analyses (all models included country, age at recruitment, date of 299 
blood donation, fasting status, and type of control) were performed for each of the four outcome 300 
variables with the aim to identify independent determinants of log2HbAA, log2HbGA, 301 
log2(HbAA+HbGA), and HbGA/HbAA (Table 3). Analyses stratified by alcohol intake and by BMI 302 
were performed, but no major differences were observed, thus, only overall results are presented.  303 
The HbAA model explained 30% of the variation in HbAA levels, and the food groups ‘salty biscuits, 304 
aperitif biscuits, crackers’, ‘dry cakes, biscuits’, and ‘vegetables’ were statistically significant 305 
positively associated with log2HbAA values, whereas ‘tea’ was inversely associated . 306 
The HbGA model explained 26% of the variation of HbGA levels, and the following groups were 307 
statistically significantly associated with HbGA-log levels: ‘salty biscuits, aperitif biscuits, crackers’, 308 
‘dry cakes, biscuits’, and ‘deep frying fats’. Alcohol intake was inversely associated with log2HbGA 309 
values.  310 
The HbAA+HbGA model explained 29% of the variation of the sum of total adducts levels, and only 311 
‘salty biscuits, aperitif biscuits, crackers’, ‘dry cakes, biscuits’, and ‘deep frying fats’ were 312 
significantly associated with the sum of total adducts levels.  313 
The HbGA/HbAA model explained 13% of the variation in HbGA/HbAA ratio, and BMI was 314 
positively associated, whereas alcohol consumption at recruitment was inversely associated with the 315 
HbGA/HbAA ratio. No other lifestyle variable explained variation in the ratio. 316 
Multiple linear regression analyses were also performed by European region (data not shown). The 317 
three different models from the northern countries explained a higher variation in HbAA, HbGA, and 318 
HbAA+HbGA levels than the southern countries; however, the food groups identified as dietary 319 
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determinants of Hb-adducts levels by European region were, in general, similar to those presented in 320 
table 3.  321 
DISCUSSION 322 
The present study was carried out with the aim to identify independent determinants of HbAA, HbGA, 323 
HbAA+HbGA, and HbGA/HbAA. We investigated these associations in a cross-sectional study of 801 324 
non-smoking postmenopausal women from the EPIC cohort. The most important determinants of 325 
HbAA, HbGA, and HbAA+HbGA adduct levels were ‘salty biscuits, aperitif biscuits, and crackers’, 326 
and ‘dry cakes and biscuits’; whereas alcohol intake and BMI (inversely and positively associated, 327 
respectively) were identified as the two main determinants of HbGA/HbAA ratio.  328 
To our knowledge, there are only three published studies that evaluated the relation between specific 329 
food group determinants and Hb-adducts of acrylamide and glycidamide, and all of them obtained 330 
dietary information through DQs [16–18]. The first study was based on a Norwegian population, and 331 
included 19 men and 31 women (n=50) of which 14% of the subjects were smokers. The second study 332 
comprised 296 female, non-smoking, pre- and postmenopausal women from the Nurses’ Health Study 333 
II (NHS-II). The Danish study, similar to the present study, was based on postmenopausal women who 334 
reported being non-smokers at baseline (n=537).  335 
The current study had the highest estimated intake of acrylamide compared to the Norwegian and the 336 
NHS-II studies. The Norwegian study reported a median acrylamide intake of 12.8 µg/day among 337 
non-smoking women (in EPIC, 20.3 µg/day), and the NHS-II study reported a mean energy-adjusted 338 
intake of 19.3 µg/day (in EPIC, 21.9 µg/day). The Danish study did not report information on overall 339 
dietary acrylamide intake.  340 
Blood samples from both EPIC and NHS-II studies were measured in the same laboratory using the 341 
same protocol. Likewise, the Norwegian and the Danish studies shared the same methodology [16, 342 
17]. The median adduct levels for HbAA and HbGA in the present study (41.3 and 34.2 pmol/g of Hb, 343 
respectively) were higher than the values reported in the Norwegian (36.8 and 18.2 pmol/g of Hb), and 344 
the Danish (35 and 21pmol/g of Hb) studies; however, the NHS-II study reported the highest values of 345 
15 
 
Hb-adducts (43.9 and 49.4 pmol/g of Hb). The NHS-II study also had the highest median values of 346 
HbGA/HbAA (1.10), compared to the Norwegian (0.49), and the present (0.8) study.  347 
The correlation between estimated acrylamide intake (based on DQs), and Hb-adducts of acrylamide 348 
and glycidamide was low (ranging from 0.08 to 0.43) in most studies, including EPIC [15, 16, 32–34]. 349 
The NHS-II study reported moderate correlations between acrylamide intake and HbAA or HbGA 350 
(0.19-0.35). These differences could be due to errors in dietary assessment methods, and to incomplete 351 
data on acrylamide content in food composition databases. The NHS-II acrylamide database was 352 
mainly based on values from the FDA’s Exploratory Analysis of Acrylamide in Foods, but specific 353 
foods that were frequently consumed in the study were further analyzed, such as different brands of 354 
breakfast cereals, dried food, bread, and potatoes chips among others [18].   355 
The main food group determinants of Hb-adducts (HbAA, HbGA, and HbAA+HbGA) in the present 356 
study were ‘salty biscuits, aperitif biscuits, and crackers’, and ‘dry cakes, and biscuits’; whereas 357 
Freisling et al. reported that ‘bread, crisp bread, and rusks’, ‘coffee’, and ‘potatoes’, were the main 358 
determinants of dietary acrylamide intake (based on a single 24 hDR) in a different subgroup of EPIC 359 
men and women [5]. Coffee was selected in the stepwise procedure as one of the food determinants of 360 
HbGA, and HbAA+HbGA in the present study, but was not statistically significant. Inverse 361 
associations between ‘tea’ and Hb-adduct levels (HbAA, HbGA, and HbAA+HbGA) were observed in 362 
the present study. This result may be explained by the possible effect of tea polyphenols, which have 363 
been observed to decrease HbAA levels in animals [35].  The variable ‘vegetables’ was selected as a 364 
determinant of log2HbAA; however, this result might has been confounded by other acrylamide 365 
containing foods, since ‘vegetables’ includes all forms of cooking methods (including frying and 366 
baking). The food groups ‘bread, crisp bread, rusks’, and ‘potatoes’ were not selected in any of the 367 
models presented in this study; however the possible effect of ‘potatoes’, especially fried potatoes, 368 
might have been represented by the variable ‘deep frying fats’. It is worth noting that the present study 369 
was evaluating adducts levels, whereas the Friesling et al. study was evaluating acrylamide intake 370 
based on 24 hDR. Further, differences in the results of these two EPIC analyses may reflect 371 
differences in the subpopulation studied (e.g, age distribution, sex, menopausal status).  372 
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The Norwegian study identified as dietary determinants of HbAA levels ‘potatoes’, ‘chips/snacks’, 373 
‘crisp bread’, and ‘jam/preservatives. Furthermore, ‘chips/snacks’, and ‘crisp bread’ were also 374 
recognized as determinants of HbAA+HbGA. Similar to EPIC, the NHS-II study also identified 375 
dietary determinants of HbAA, HbGA, and HbAA+HbGA; but the food groups were different from 376 
the determinants observed in the present study. The Danish study reported ‘coffee’ to be associated 377 
with HbAA and HbGA, ‘chips’ to HbAA, and ‘biscuits/crackers’ to HbGA levels. Dietary habits are 378 
different between the US and European countries, so direct comparison of food groups as determinants 379 
of HbAA levels may not be possible.  380 
The proportion of response variation (R2) explained by food groups and/or lifestyle variables in the 381 
present study varied from 13% in the HbGA/HbAA model to 30% for HbAA. The Danish study 382 
obtained a response variation of 17% and 12% in the HbAA and HbGA models respectively; however 383 
the highest response variations explained were obtained in the Norwegian study (48% in the HbAA, 384 
and 37% in the HbAA+HbGA model) [16, 17]. The NHS-II study did not report this information [18]. 385 
The main difference between our study and the other three published studies is that prior analyses only 386 
included dietary variables that were suspected to be sources of acrylamide intake. The current study 387 
included both known sources of dietary acrylamide together with lifestyle variables, such as alcohol 388 
intake and BMI, with the intention to better describe the independent determinants of Hb-adducts and 389 
their ratio in non-smoking individuals. Diet is complex, and interactions between acrylamide and food 390 
ingredients are possible (i.e, acrylamide uptake in humans has been hypothesized to be impaired by a 391 
diet rich in proteins) [26]. Likewise, it has been suggested that alcohol intake and BMI may influence 392 
the activity of Cyp2e1, the enzyme complex that metabolizes acrylamide to glycidamide. This enzyme 393 
is involved in alcohol metabolism mainly when alcohol concentrations in the blood are high. It has 394 
been hypothesized that alcohol may compete with acrylamide as a substrate [36]. This could partially 395 
explain the results observed in the present study; in which higher alcohol intake was inversely 396 
associated with HbGA and HbGA/HbAA, as has been reported in other studies [14, 36]. The 397 
mechanism by which BMI may influence acrylamide metabolism is still unclear, but similar to the 398 
present study, other studies have observed that BMI was positively associated with the ratio 399 
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HbGA/HbAA, and negatively associated with HbAA [14, 37, 38]. Recently, statistically significant 400 
differences in the ratio of HbGA/HbAA between vegetarians and non-vegetarians have been reported, 401 
suggesting that dietary factors may also contribute to acrylamide/glycidamide metabolism [39]. 402 
The present study had the largest sample size compared to the previous published papers, and the 403 
laboratory methods used to quantify both acrylamide and glycidamide hemoglobin adducts were 404 
standardized and followed rigorous quality assurance/quality control [12]. Tobacco is one of the most 405 
important sources of acrylamide, and it is well-established that cigarette smoke influences Hb-adducts 406 
levels (smokers have mean HbAA levels at least three to four times higher than non-smokers) [11, 14]. 407 
Moreover, it has been hypothesized that acrylamide may influence hormonal homeostasis [40–42]. 408 
Thus, the present study was designed to reduce confounding by these factors, and only those women 409 
who reported being postmenopausal and never smokers were included in the study. Further, 410 
limitations derived from using estimates of dietary acrylamide intake, as described above, were 411 
avoided in the present analysis of food groups and biomarkers levels.  412 
There are some limitations that should be acknowledged: a) Hb-adducts of acrylamide and 413 
glycidamide are valid biomarkers for acrylamide exposure and internal dose; however, these adducts 414 
reflect levels of acrylamide and glycidamide during the average lifespan of erythrocytes, which is 415 
around 120 days [1, 10], and all dietary and lifestyle variables in EPIC were assessed through DQs 416 
that referred to the previous year before recruitment [19]. b) Cooking methodology, which influences 417 
acrylamide levels in food, was not recorded in some EPIC centers; however, relevant information on 418 
food preparation was available for potatoes (except in Italy), bread, and breaded meats [15, 24]. c) 419 
Only one baseline blood sample was collected for each participant. d) Acrylamide content in foods 420 
may vary seasonally [43], which was not accounted for in our analyses; nevertheless, all models were 421 
adjusted for date of blood extraction to minimize this effect. (e) Ferrari et al. described variations in 422 
dietary patterns across EPIC countries [15], and this may have influenced Hb-adducts levels and our 423 
prediction models, although all models included country to adjust for country-level effects (i.e. 424 
questionnaire design, dietary habits). f) SHS could not be evaluated in our statistical models due to the 425 
large number of missing values (>50%); however, in a subset of women from the current study, no 426 
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statistically significant differences in Hb-adduct levels were observed between women who were 427 
exposed to SHS and who were not exposed to SHS. 428 
To conclude, dietary food group and lifestyle variables explain a moderate proportion of HbAA and 429 
HbGA adduct level variation in 801 postmenopausal non-smoking women in the EPIC cohort. The 430 
main food groups determinants of HbAA, HbGA, and HbAA+HbGA were ‘Salty biscuits, aperitif 431 
biscuits, and crackers’, and ‘dry cakes, and biscuits’. Alcohol intake and BMI were identified as the 432 
principal determinants for the ratio HbGA/HbAA levels. In this regard, future studies assessing 433 
associations between acrylamide and disease risk should take into consideration the use of both 434 
biomarkers of acrylamide exposure (HbAA and HbGA), in addition to alcohol intake and BMI.   435 
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Table 1. Estimated dietary acrylamide intake and hemoglobin acrylamide and glycidamide adducts levels by EPIC country in a subgroup of non-smoking postmenopausal women  
 Total 
observations  
Endometrial 
controls 
Ovarian 
controls 
  
Acrylamide intake 
HbAA          
pmol/g of Hb 
HbGA        
pmol/g of Hb 
HbAA+HbGA           
pmol/g of Hb 
 Ratio of 
HbGA/HbAA 
 
Acrylamide 
intake (µg/day) 
Acrylamidea 
intake (µg/day) 
µg/ kg-body 
weight/day 
EPIC country n (%) n (%) n (%) Median (QR) Median (QR) Median (QR) Median (QR) Median (QR) Median (QR) Median (QR) 
France 65 (8) 35 (9) 30 (7) 20.0 (14.5- 25.6) 17.6 (13.5- 21.6) 0.3 (0.2- 0.4) 38.5 (34.2- 47.3) 29.4 (24.6- 36.8) 66.4 (60.1- 82.9) 0.7 (0.7- 0.8) 
Italy 126 (16) 74 (19) 52 (12) 8.6 (5.5- 11.5) 7.8 (4.1- 10.7) 0.1 (0.1- 0.2) 35.8 (26.7- 44.9) 28.9 (21.9- 38.2) 64.7 (49.8- 87.7) 0.8 (0.7- 0.9) 
Spain 127 (16) 72 (19) 55 (13) 16.6 (9.8- 25.9) 19.0 (13.0- 25.4) 0.2 (0.1- 0.4) 42.4 (33.8- 53.8) 39.8 (28.6- 48.6) 82.4 (62.9- 101.5) 0.9 (0.8- 1.0) 
United 
Kingdom 
153 (19) 59 (15) 94 (23) 31.4 (23.8- 40.4) 30.5 (24.2- 39.5) 0.5 (0.3- 0.6) 55.6 (44.4- 69.0) 47.1 (35.2- 61.3) 102.9 (83.1- 133.4) 0.8 (0.7- 1.0) 
The Netherlands 116 (14) 38 (10) 78 (19) 28.8 (19.4- 40.0) 30.0 (22.1- 40.4) 0.4 (0.3- 0.6) 45.3 (37.2- 54.4) 38.6 (29.5- 51.7) 80.9 (68.0- 105.2) 0.9 (0.7- 1.0) 
Greece 59 (7) 16 (4) 43 (10) 17.7 (14.4- 21.9) 19.1 (17.5- 22.8) 0.2 (0.2- 0.3) 26.4 (21.1- 35.3) 22.0 (16.5- 31.8) 50.4 (40.1- 67.1) 0.9 (0.7- 1.0) 
Germany 102 (13) 56 (15) 46 (11) 22.8 (18.5- 29.5) 24.9 (19.9- 29.2) 0.3 (0.2- 0.5) 36.2 (29.7- 43.8) 29.3 (23.1- 38.5) 67.2 (53.0- 78.5) 0.8 (0.7- 0.9) 
Sweden 53 (7) 34 (9) 19 (5) 18.3 (14.8- 21.0) 22.6 (20.5- 25.0) 0.3 (0.2- 0.3) 38.5 (34.9- 46.9) 34.6 (25.9- 42.2) 72.8 (62.9- 87.8) 0.9 (0.8- 1.0) 
Total 801 384 417 20.3 (13.5-29.9) 21.9 (14.6-29.2) 0.3 (0.2-0.5) 41.3 (32.8-53.1) 34.2 (25.4-46.9) 75.5 (58.5-100.0) 0.8 (0.7-1.0) 
EPIC, European Prospective Investigation into Cancer and Nutrition; QR, quartile range, HbAA, hemoglobin adducts of acrylamide; HbGA, hemoglobin adducts of glycidamide; Hb, 
hemoglobin 
a Energy-adjusted using the residual method 
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Table 2. Simple linear regression with β-estimates for the association between dietary and lifestyle variables and log-transformed (log2) 
HbAA, HbGA, HbAA+HbGA, and HbGA/HbAA. 
Variables 
Log2HbAA Log2HbGA HbAA+HbGA HbGA/HbAA 
β P-value β P-value β P-value β P-value 
Acrylamide intake (µg/day) 0.20 <.0001 0.23 <.0001 0.21 <.0001 0.02 0.02 
Age at recruitment (y) -0.003 0.26 0.001 0.79 -0.002 0.60 0.002 0.03 
Body mass index (kg/m2) -0.32 <.0001 -0.01 0.91 -0.18 0.02 0.17 <.0001 
Alcohol intake (g/day) 0.01 0.04 -0.01 0.09 0.002 0.79 -0.01 <.0001 
Total dietary fiber (g/day) 0.17 <.0001 0.15 0.002 0.16 0.0001 -0.01 0.53 
Total proteins (g/day) 0.15 0.0003 0.18 0.0003 0.17 0.0002 0.01 0.30 
Meat and meat products (g/day) -0.02 0.20 0.00 0.78 -0.01 0.58 0.01 0.01 
Potatoes and other tubers (g/day) 0.04 <.0001 0.05 <.0001 0.05 <.0001 0.01 0.16 
Vegetables (g/day) 0.05 0.01 0.03 0.17 0.04 0.03 -0.01 0.10 
Fruits, nuts, and seeds (g/day) -0.02 0.21 -0.02 0.32 -0.02 0.25 0.002 0.78 
Olives (g/day) -0.05 <.0001 -0.05 <.0001 -0.05 <.0001 0.001 0.79 
Cereal and cereal products (g/day) -0.02 0.51 -0.02 0.47 -0.02 0.51 0.00003 1.00 
Flour, flakes, starches, semolina (g/day) -0.07 <.0001 -0.06 <.0001 -0.06 <.0001 0.004 0.25 
Pasta, rice, other grains (g/day) -0.02 0.02 -0.03 0.01 -0.02 0.01 -0.002 0.48 
Bread, crisp bread and rusks (g/day) -0.04 0.01 -0.03 0.10 -0.04 0.03 0.007 0.19 
Breakfast cereals (g/day) 0.04 <.0001 0.03 <.0001 0.04 <.0001 -0.002 0.34 
Salty biscuits, aperitif biscuits, crackers (g/day) 0.04 <.0001 0.04 <.0001 0.04 <.0001 -0.003 0.21 
Dry cakes, biscuits (g/day) 0.02 0.0003 0.03 <.0001 0.03 <.0001 0.005 0.02 
Pastries (g/day) -0.02 0.06 -0.04 0.0001 -0.03 0.004 -0.01 <.0001 
Cakes, biscuits (g/day) 0.03 0.0003 0.04 <.0001 0.03 <.0001 0.004 0.14 
Chocolate, candy, paste, confetti (g/day)  0.03 <.0001 0.03 <.0001 0.03 <.0001 0.001 0.51 
Confectionery non-chocolate, candied fruits 
(g/day) 0.02 0.004 0.03 0.004 0.02 0.003 0.002 0.41 
Snacks (g/day) 0.05 <.0001 0.06 <.0001 0.05 <.0001 0.002 0.35 
Olive oil (g/day) -0.04 <.0001 -0.04 <.0001 -0.04 <.0001 0.002 0.33 
Deep frying fats (g/day) 0.03 0.04 0.03 0.03 0.03 0.03 0.004 0.36 
Tea (ml/day) 0.02 <.0001 0.02 0.0001 0.02 <.0001 -0.002 0.06 
Coffee (ml/day) 0.02 0.001 0.02 0.01 0.02 0.002 -0.0001 0.98 
Decaffeinated coffee (ml/day) 0.02 <.0001 0.03 <.0001 0.03 <.0001 0.002 0.24 
Energy intake (kcal/day) 0.13 0.01 0.13 0.02 0.13 0.01 -0.0001 0.99 
HbAA, hemoglobin adducts of acrylamide, HbGA, hemoglobin adducts of glycidamide 
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All independent variables were log-transformed (log2) to improve normality. 
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Table3. Multiple linear stepwise regression with β-estimates and standard errors for the association between dietary and lifestyle 
variables and log-transformed (log2) HbAA, HbGA, HbAA+HbGA, and HbGA/HbAA. 
Hemoglobin 
Dietary and/or life style variables β (SE) P-value Partial R2 Model R2 
 adducts 
L
o
g
2
H
b
A
A
 
Salty biscuits, aperitif biscuits, crackers 0.03 (0.01) 0.0001 0.01 
0.3 
Dry cakes, biscuits 0.02 (0.01) 0.003 0.01 
Tea -0.01 (0.005) 0.02 0.01 
Vegetables 0.05 (0.02) 0.02 0.005 
BMI -0.15 (0.07) 0.05 0.004 
Deep frying fats 0.04 (0.02) 0.08 0.003 
L
o
g
2
H
b
G
A
 
Dry cakes, biscuits 0.03 (0.01) 0.0001 0.02 
0.26 
Salty biscuits, aperitif biscuits, crackers 0.03 (0.01) 0.0002 0.01 
Alcohol at recruitment -0.02 (0.01) 0.01 0.01 
Deep frying fats 0.07 (0.03) 0.02 0.01 
Coffee 0.01 (0.01) 0.06 0.003 
Tea -0.01 (0.01) 0.07 0.003 
L
o
g
2
 (
H
b
A
A
+
H
b
G
A
) Salty biscuits, aperitif biscuits, crackers 0.03 (0.01) 0.0001 0.01 
0.29 
Dry cakes, biscuits 0.02 (0.01) 0.0005 0.01 
Tea -0.01 (0.005) 0.02 0.005 
Deep frying fats 0.05 (0.02) 0.03 0.004 
Fiber 0.07 (0.04) 0.05 0.003 
Coffee 0.01 (0.01) 0.08 0.003 
H
b
G
A
/H
b
A
A
  
BMI 0.14 (0.03) <0.0001 0.03 
0.13 
Alcohol at recruitment -0.01 (0.002) 0.00002 0.02 
Education level    
None reference - 
0.006 
Primary school completed -0.01 (0.02) 0.73 
Technical/professional school -0.02 (0.03) 0.51 
Secondary school -0.02 (0.03) 0.61 
Higher education -0.06 (0.03) 0.05 
Not specified 0.02 (0.05) 0.70 
Missing -0.04 (0.07) 0.53 
Ever use of OCs    
No reference -  
Yes -0.02 (0.01) 0.12 
0.003 
Missing 0.04 (0.06) 0.53 
Physical activity    
Inactive reference - 
0.003 
Moderately inactive 0.02 (0.02) 0.28 
Moderately active -0.02 (0.02) 0.29 
Active 0.01 (0.02) 0.77 
Missing -0.03 (0.09) 0.74 
Ever use of HRT    
No reference -  
Yes 0.004 (0.02) 0.81 
0.002 
Missing -0.05 (0.04) 0.22 
Diabetes    
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No reference -  
Yes 
-0.02 (0.03) 0.47 
0.001 
Missing -0.03 (0.07) 0.64 
SE, standard error; HbAA, hemoglobin adducts of acrylamide; HbGA, hemoglobin adducts of glycidamide; BMI, body mass index (kg/m2); 
HRT, hormonal replacement therapy; OC, oral contraceptive. 
All models are adjusted for country, age at recruitment (y), date of blood donation, fasting status (no, in between, yes), and type of control 
(endometrial, ovarian control). All independent continuous variables were log-transformed (log2) to improve normality. 
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Figure 1. Box-and-whisker plot of HbGA/HbAA ratio versus alcohol consumption (never drinkers, ever drinkers). 
Arrow marks significant differences between groups. P-value based on a Wilcoxon rank sum test. 
 
 
Figure 2. Box-and-whisker plot of HbGA/HbAA ratio versus body mass index (BMI; <25, 25-30, ≥30 kg/m2).Arrow 
marks significant differences between groups. P-values based on a Wilcoxon rank sum test. 
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Supplemental table 1. Baseline characteristics of the 801 non-smoking postmenopausal women 
Variables Mean SD P5 P25 Median P75  P95 
Lifestyle variables         
Age at recruitment (y) 58.79 6.30 49.29 54.33 58.83 63.06 69.44 
Body Mass Index (kg/m2) 26.73 4.90 20.07 23.21 25.96 29.41 36.07 
Alcohol at recruitment (g/d) 6.04 8.63 0.00 0.18 2.13 8.87 24.26 
Dietary variables (g/day) 
       Total dietary fiber 22.45 7.02 12.28 17.76 21.73 26.28 34.70 
Total proteins  83.02 25.34 45.70 65.42 81.00 97.23 128.04 
Meat and meat products  90.88 48.77 21.05 56.34 84.03 121.54 175.53 
Potatoes and other tubers  78.00 58.92 7.09 32.90 67.11 114.85 178.94 
Vegetables 215.85 139.33 56.35 114.68 183.18 292.20 472.48 
Olives 1.30 4.44 0.00 0.00 0.00 0.03 8.57 
Fruits, nuts, seeds  289.73 179.12 69.58 161.15 259.53 376.37 628.21 
Flour, flakes, starches, semolina 0.56 2.13 0.00 0.00 0.00 0.16 2.54 
Pasta, rice, other grains 58.64 56.09 3.36 20.03 41.86 80.12 176.62 
Cereal and cereal products 198.09 93.95 79.97 135.42 182.42 241.91 375.86 
Bread, crisp bread, rusks 116.16 65.97 28.80 69.50 104.77 152.00 234.88 
Breakfast cereals 17.25 45.85 0.00 0.00 0.00 11.17 115.10 
Salty biscuits, aperitif biscuits, crackers 2.14 5.10 0.00 0.00 0.22 2.14 11.43 
Dry cakes, biscuits 9.63 20.88 0.00 0.00 3.44 12.32 38.93 
Pastries 0.91 2.00 0.00 0.00 0.00 0.99 4.62 
Cakes and biscuits 46.57 47.92 0.00 15.35 34.43 63.76 128.57 
Chocolate, candy bars, paste, confetti 6.26 11.21 0.00 0.00 2.00 8.04 25.00 
Confectionery non-chocolate, candied fruits 2.57 7.10 0.00 0.00 0.13 1.67 12.90 
Snacks 2.29 9.26 0.00 0.00 0.00 0.21 10.01 
Olive oil 9.00 14.06 0.00 0.00 0.47 15.22 39.51 
Deep frying fats 0.32 1.04 0.00 0.00 0.00 0.00 2.03 
Tea 220.49 318.36 0.00 0.00 41.42 375.00 855.00 
Coffee 282.75 262.19 0.00 70.00 191.90 475.00 750.00 
Decaffeinated coffee 38.39 110.55 0.00 0.00 0.00 3.57 250.00 
Energy intake (kcal/day) 1,913.10 550.34 1,132.44 1,529.36 1,842.57 2,214.45 2,861.80 
SD, Standard deviation; P5, 5th percentile, P25, 25th percentile; P75, 75th percentile; P95, 95th percentile 
 
 
